Company Profile

MANGALAM DRUGS & ORGANICS LTD.

NSE : MANGALAMBSE : 532637ISIN CODE : INE584F01014Industry : Pharmaceuticals & DrugsHouse : Private
BSE33.70-0.05 (-0.15 % )
PREV CLOSE (Rs.) 33.75
OPEN PRICE (Rs.) 33.70
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 100
TODAY'S LOW / HIGH (Rs.)33.70 33.70
52 WK LOW / HIGH (Rs.)28 90.5
NSE34.55 0.7 (+2.07 % )
PREV CLOSE(Rs.) 33.85
OPEN PRICE (Rs.) 34.95
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 34.55 (123 )
VOLUME 12489
TODAY'S LOW / HIGH(Rs.) 33.15 34.95
52 WK LOW / HIGH (Rs.)28.05 89.25

Smart Quotes

1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Trade Value (Rs. in Lacs) 0.0337
Dividend Yield(%)
TTM EPS (Rs.)
P/E Ratio
Book Value (Rs.)
Face Value (Rs.)
MCap (Rs. in Mn)
Price/Earning (TTM)
Price/Sales (TTM)
Price/Book (MRQ)
PAT Margin (%) 6.46
ROCE (%) 25.24
Incorporation Year : 1972

Management Info :

Govardhan M Dhoot - Chairman Govardhan M Dhoot - Managing Director

Registered Office :

Address : ‘3” Floor,237, Rupam Building,P. D. Mello Road,
Mumbai,
Maharashtra-400001

Phone : 91-22-22616200/ 6300/8787

Registrar's Details : Link Intime India Pvt Ltd.
C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai
Listing : BSE, NSE
NEWS More
30Jul07-30-2019$Mangalam Drugs & Organics informs about newspaper publication Mangalam Drugs & Organics in

Pursuant to Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Mangalam Drugs & Organics has informed about submission of copies of newspaper advertisement published in Free Press Journal (English daily) and Navshakti (Marathi daily), Mumbai editions, both dated July 27, 2019 in which Un-Audited Financial Results of the Company for the quarter ended June 30, 2019 have been published. The aforesaid results have been approved by the Board of Directors in its meeting held on July 26, 2019.

The above information is a part of company’s filings submitted to BSE.

Pursuant to Regulation 47 of SEBI (Listing Obligations and Disc..
22Jul07-22-2019$Mangalam Drugs & Organics informs about clarification Mangalam Drugs & Organics in

Mangalam Drugs & Organics has informed that the Company is in no way concerned with the movement in price of security across Exchanges.Any such movement in price of securities is purely based on the market sentiments of the investor .

The above information is a part of company’s filings submitted to BSE.

Mangalam Drugs & Organics has informed that the Company is..
08Jul07-08-2019$ Announcement under Regulation 30 (LODR)-Change in Directorate Announcement under Regulati
In terms of Regulation 30(2) read with part A of Schedule III of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, we have to inform you that the Board of Directors of the Company, in their meeting held today i.e. Monday, 8th July, 2019 has approved the appointment of Mr. Prashant J. Pandit (DIN: 03079878) as an Additional Non-Executive Independent Director w.e.f. 8th July, 2019. We request you to take the same on your records.
In terms of Regulation 30(2) read with part A of Schedule III o..
08Jul07-08-2019$ Announcement under Regulation 30 (LODR)-Change in Directorate Announcement under Regulati
In terms of Regulation 30(2) read with part A of Schedule III of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, we have to inform you that the Board of Directors of the Company, in their meeting held today i.e. Monday, 8th July, 2019 has approved the appointment of Mr. Prashant J. Pandit (DIN: 03079878) as an Additional Non-Executive Independent Director w.e.f. 8th July, 2019. We request you to take the same on your records.
In terms of Regulation 30(2) read with part A of Schedule III o..
15May05-15-2019$Resignation of Director Resignation of Director
inter alia, approved the following: 1. Noted the Resignation of Mr. Ajay Sawhney as an Independent Director of the Company with effect from 16th April, 2019 due to his personal reasons.
inter alia, approved the following: 1. Noted the Resignation of..
Financials More
Rs. in Millions
QTR Jun 19 ANNUAL 19
Net Profit7.39-80.31
Gross Profit 10.43 -57.37
Operating Profit 54.9399.98
Net Sales 650.422275.8
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group More
Astrazeneca Pharma I (BSE)
 1708.40 (1.53%)
M.Cap ( in Cr)
4271.00
Everest Organics (BSE)
 172.65 (17.45%)
M.Cap ( in Cr)
138.12
Piramal Enterprises (BSE)
 1782.55 (0.90%)
M.Cap ( in Cr)
35445.39
Ajanta Pharma (BSE)
 996.45 (1.56%)
M.Cap ( in Cr)
8694.50
Samrat Pharmachem (BSE)
 73.20 (20.00%)
M.Cap ( in Cr)
22.62
Shareholding Pattern More
PROMOTERS 50.53 %
NON-INSTITUTION 49.44 %
FI/BANKS/INSURANCE 0.03 %
MUTUAL FUNDS/UTI 0 %
GOVERNMENT 0 %
FII 0 %
MF HOLDINGS
Scheme NameHold(%)
No Data Found
F & O Quotes